| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $4,947,774 ) |
| | 2025 | 2025 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-5509 | NEW YORK | USA | U01DA061643 | Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder | 000 | 2 | NIH | 4/23/2025 | $4,947,774 |
| | 2025 | 2024 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-5509 | NEW YORK | USA | UH3DA048234 | Development of a novel drug for treating opioid use disorder | 000 | 5 | NIH | 10/16/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $7,836,460 ) |
| | 2024 | 2024 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-5509 | NEW YORK | USA | UH3DA048234 | Development of a novel drug for treating opioid use disorder | 001 | 5 | NIH | 8/29/2024 | $3,051,459 |
| | 2024 | 2024 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-5509 | NEW YORK | USA | U01DA061643 | Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder | 001 | 1 | NIH | 8/20/2024 | $0 |
| | 2024 | 2024 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-5509 | NEW YORK | USA | U01DA061643 | Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder | 000 | 1 | NIH | 7/31/2024 | $4,785,001 |
| | 2024 | 2024 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-5509 | NEW YORK | USA | U01DA061643 | Select Late-Stage CMC, Non-clinical Studies, and Quality Programs to Accelerate NRS-033 Towards Pivotal Studies and Registration in Opioid Use Disorder | 002 | 1 | NIH | 8/29/2024 | $0 |
| | 2024 | 2023 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-5509 | NEW YORK | USA | UH3DA048234 | Development of a novel drug for treating opioid use disorder | 000 | 4 | NIH | 8/28/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,052,891 ) |
| | 2023 | 2023 | NIRSUM LABORATORIES LLC | 200 VESEY ST | NEW YORK | NY | 10281 | NEW YORK | USA | UH3DA048234 | Development of a novel drug for treating opioid use disorder | 002 | 4 | NIH | 8/30/2023 | $3,052,891 |
| | 2023 | 2023 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-5509 | NEW YORK | USA | UH3DA048234 | Development of a novel drug for treating opioid use disorder | 003 | 4 | NIH | 9/27/2023 | $0 |
| | 2023 | 2022 | NIRSUM LABORATORIES LLC | 200 VESEY ST | NEW YORK | NY | 10281 | NEW YORK | USA | UH3DA048234 | Development of a novel drug for treating opioid use disorder | 000 | 3 | NIH | 10/27/2022 | $0 |
| | 2023 | 2022 | NIRSUM LABORATORIES LLC | 200 VESEY ST | NEW YORK | NY | 10281 | NEW YORK | USA | UH3DA048234 | Development of a novel drug for treating opioid use disorder | 001 | 3 | NIH | 1/26/2023 | $0 |
| | 2023 | 2020 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-5509 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 000 | 2 | NIH | 8/9/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $3,056,516 ) |
| | 2022 | 2022 | NIRSUM LABORATORIES LLC | 200 VESEY ST | NEW YORK | NY | 10281 | NEW YORK | USA | UH3DA048234 | Development of a novel drug for treating opioid use disorder | 000 | 3 | NIH | 9/15/2022 | $3,056,516 |
| | 2022 | 2020 | NIRSUM LABORATORIES LLC | 200 VESEY ST | NEW YORK | NY | 10281 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 001 | 2 | NIH | 9/14/2022 | $0 |
| | 2022 | 2020 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-1004 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 000 | 2 | NIH | 1/27/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $164,132 ) |
| | 2021 | 2021 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-1004 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 001 | 2 | NIH | 3/3/2021 | $164,132 |
| | 2021 | 2020 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-1004 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 000 | 2 | NIH | 2/5/2021 | $0 |
| | 2021 | 2020 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-1004 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 002 | 2 | NIH | 7/16/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $3,058,678 ) |
| | 2020 | 2020 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-1004 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 001 | 2 | NIH | 2/26/2020 | $3,058,678 |
| | 2020 | 2019 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-1004 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 000 | 1 | NIH | 12/19/2019 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $3,060,540 ) |
| | 2019 | 2019 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-1004 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 001 | 1 | NIH | 4/25/2019 | $0 |
| | 2019 | 2019 | NIRSUM LABORATORIES, INC. | 200 VESEY ST FL 24 | NEW YORK | NY | 10281-1004 | NEW YORK | USA | UG3DA048234 | Development of a novel drug for treating opioid use disorder | 000 | 1 | NIH | 3/14/2019 | $3,060,540 |
|
|
